Upper Respiratory (26 targets)
Upper Respiratory (26 targets)

[Product Name]

26 Upper Respiratory Tract Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method)

 Upper Respiratory (26 targets)CHE-URP26-101

[Packing Specifications]

12 tests / box

[Applicable Models]

Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Upper Respiratory (26 targets)Chenghui-Multi-Disc-26-Upper-Respiratory-Tract-Pathogen-Nucleic-Acid-Detection-Kit-Brochure.pdf




No Data

Testing Process

No Data

Intended Use


26 Upper Respiratory Tract Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of 26 pathogens in human nasopharyngeal swab samples, including: 

  1. SARS-CoV-2, 

  2. Influenza A Virus, 

  3. Influenza A/H3, 

  4. Influenza A H1N1 pdm09 Virus, 

  5. Influenza A/H1, 

  6. Influenza A/H5, 

  7. Parainfluenza virus type I-IV, 

  8. Coronavirus 229E, 

  9. Coronavirus OC43, 

  10. Coronavirus NL63, 

  11. Coronavirus HKU1, 

  12. Rhinovirus, 

  13. Respiratory syncytial virus A, 

  14. Respiratory syncytial virus B, 

  15. Influenza B Yamagata, 

  16. Influenza B Victoria, 

  17. Bocavirus, 

  18. Enterovirus, 

  19. Human metapneumovirus, 

  20. Adenovirus, 

  21. Mycoplasma pneumoniae, 

  22. Bordetella pertussis, 

  23. Bordetella parapertussis, 

  24. Bordetella holmesii, 

  25. Legionella pneumophila,

  26. Middle East Respiratory Syndrome Coronavirus (MERS-CoV),

  27. Chlamydia pneumoniae*(RUO).


Remark: The CE marking certificate is not yet acquired for the detection target of Chlamydia pneumoniae. Nevertheless, we are able to supply this test target solely for research use only (RUO).


Clinical Challenges & Core Clinical Benefits


Clinical Challenges


Difficult Clinical Differential Diagnosis

Upper respiratory tract infections share highly overlapping symptoms including fever, cough, sore throat and dyspnea, particularly in severe inpatients and immunocompromised populations. Mixed infections are common in critical cases, making empirical judgment unreliable and targeted treatment difficult to implement.


Limited Traditional Detection Capability

Conventional microbial culture takes 3–7 days with a positive rate of only 40%–60%, while single-target PCR assays have narrow pathogen coverage. Neither method can simultaneously detect viruses, atypical pathogens and bacteria, easily leading to missed diagnosis, delayed treatment and irrational antibiotic use.


Cumbersome & Inefficient Conventional Workflow

Traditional nucleic acid testing requires dedicated PCR laboratories and well-trained technicians, with multi-step manual operations and long turnaround times. It cannot meet the urgent diagnostic demands of inpatient wards and intensive care units.


Core Clinical Benefits


Precise Etiological Diagnosis for Severe Care

A single nasopharyngeal swab enables simultaneous detection of 26 respiratory pathogens covering viruses, atypical pathogens and pathogenic bacteria. One-time clear etiological identification guides precise targeted therapy, reduces unnecessary empirical antibiotic use, and shortens hospital length of stay.

Upper Respiratory (26 targets)

Reliable Co-Infection & Outbreak Management Support

Accurately identifies mixed infections of multiple pathogens, providing critical evidence for individualized treatment of severe and immunocompromised patients, and supporting rapid screening and management of nosocomial respiratory infection outbreaks.


High-Efficiency Testing for Inpatient Demands

Compatible with the Multi-Disc (Model: CQ-0404) fully automated nucleic acid analyzer, the assay delivers complete results in ~80 minutes. The platform supports parallel testing of 4 samples per run, greatly improving batch detection efficiency and saving the golden diagnostic window for critically ill patients.




Core Product Advantages


Minimal Hands-on Operation | Fully Automated Workflow

Nucleic acid extraction reagents and lyophilized PCR reagents are pre-embedded on the chip. After sample loading, nucleic acid purification, amplification and result analysis are completed fully automatically, with no manual extraction required. No professional PCR laboratory or specialized operator is needed, significantly lowering the testing threshold.

Upper Respiratory (26 targets)


Unified High Sensitivity & Specificity

Unified Limit of Detection (LOD) of 500 copies/mL for all 26 targets, enabling early detection even at low viral/bacterial loads. Clinical validation data shows positive agreement of 94.12%–100.00%, negative agreement above 99.61%, and overall concordance ≥99.45%, ensuring stable and reliable results.


Single-Cartridge Built-In Quality Control

An on-chip internal control monitors the full fluidic flow and PCR reaction process, effectively eliminating false negative results and guaranteeing the testing quality of each individual cartridge.


Wide Storage & Transportation Tolerance

The kit can be stored and transported at 4–28°C with no cold chain required, and has a 12-month shelf life, reducing logistics costs and inventory management pressure for hospital customers.